


Supplementary Figures

Supplementary Figure S1 The schema of the subjects included in this survey



Abbreviation; GLP1Ra; glucagon-like peptide 1 receptor agonist; SGLT2i, sodium-glucose co-transporter inhibitor


Supplementary Figure S2 The calculation of the weight using propensity score

	The SGLT2i treated patients	The GLP1Ra-treated patients
ATE weight	1/PS	1 / (1 - PS)
ATT weight	1	PS / (1 - PS)
Stabilized ATE weight	p / PS	(1 - p) / (1 - PS)

The p value is the ratio of the SGLT2i-treated patients in total patients.


Abbreviation; ATE, average treatment effect; ATT, average treatment effect on the treated; GLP1Ra; glucagon-like peptide 1 receptor agonist; PS, propensity score; SGLT2i; sodium-glucose co-transporter inhibitor

Supplementary Figure S3 The distribution of the propensity score of SGLT2i-treated and GLP1Ra-treated patients



Abbreviation; GLP1Ra, glucagon-like-1 receptor agonist; SGLT2i, sodium glucose cotransporter inhibitor

Supplementary Figure S4 The standardized difference of the clinical characteristics at baseline depending on six models for weighting



The truncation on 99 percentiles is utilized in model A, and) the trimming by $0.05 \leq PS \leq 0.95$ is utilized in model B.

Abbreviation; BMI, body mass index; BW, body wight; CCB, calcium channel blocker; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration; HbA_{1c}, glycated hemoglobin A_{1c}; IPW, inverse probability weighting; LnACR, logarithmic value of urine albumin-to-creatinine ratio; ; MAP, mean arterial pressure; PS, propensity score; RAS, renin aldosterone system; SBP, systolic blood pressure; SGLT2i, sodium glucose cotransporter inhibitor; SU, sulphonyl urea